Akorn jumps on FDA approval. Cambridge Heart leaps on 510 k clearence. Viking Systems stock doubles. Rexahn continues it's rebound Print E-mail
By BioMedReports.com Staff   
Thursday, 15 April 2010 17:43
Below is a list of the companies that made news in the healthcare sector on Thursday, April 14, 2010.

Akorn, Inc. (NASDAQ: AKRX) exploded to the upside today after the niche generic pharmaceutical company announced that the U.S. Food and Drug Administration has granted approval of the Company’s Abbreviated New Drug Application (ANDA) for the generic version of Dilaudid-HP® 10mg/ml Injection. The company intends to begin shipping the product next month.

In addition, the Company has commenced the manufacturing of Vancomycin HCL for Injection 5gm / vial in its Decatur, IL plant on a contract basis for sale through its joint venture subsidiary, Akorn-Strides. The additional manufacturing site allows the Akorn-Strides joint venture to increase production to meet its current demand for this product.

The stock closed at $1.73, up 31 cents or 21.83%.

Cambridge Heart, Inc. (OTCBB: CAMH), soared after the company announced today that it has received clearance from the U.S. Food and Drug Administration to begin marketing its Microvolt T-Wave Alternans (MTWA) OEM module. The MTWA OEM module is designed to work with existing cardiac stress test platforms distributed by other manufacturers. This FDA 510(k) clearance allows Cambridge Heart to begin marketing the MTWA OEM module integrated with the Q-Stress line of stress systems manufactured by Cardiac Science Corporation, Inc. (NASDAQ:CSCX). The non-invasive MTWA test measures small heartbeat irregularities that indicate a patient’s heightened risk for sudden cardiac arrest.

Cambridge Heart catapulted more than 102%, closing at 71 cents, up 36 cents on the day while Cardiac Science moved up almost 4%.

Viking Systems (OTCBB:VKNG) more than doubled in price Thursday after the company announced that video captured during preclinical evaluations of the Viking 3DHD prototype visualization system will be shown in the Sony booth during the 12th World Congress of Endoscopic Surgery to be held at the Gaylord National Hotel in National Harbor, Maryland from April 14 - 17, 2010. A central focus of the 12th World Congress of Endoscopic Surgery is "The World of Technique." The program will highlight different surgical techniques and strategies from around the world. A world-class faculty will emphasize surgical techniques using didactics, images, and video to address both established and novel therapeutic modalities from North America and beyond.

"Once again, we are proud that Sony has chosen to use video captured with the Next Generation Viking System 3DHD Visualization System to demonstrate the future of minimally invasive surgical vision, especially at this venue and gathering of the world's elite MIS surgeons," said Jed Kennedy, President and CEO of Viking Systems, Inc. "This will be a great opportunity for this large group of minimally invasive surgeons to view firsthand the quality of the stand alone, cost effective 3DHD imaging Viking plans to introduce later this year," Kennedy added.

Shares of Viking Systems soared more than 18.5 cents or 115%, to 34.5 cents.

Viking Systems was highlighted by BioMedReports back in November of 2009.

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), surged higher today after the company announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.

These data on the anti-cancer activity of RX-8243 will be presented in a poster (abstract #3562) entitled, "Characterization of a novel small molecule with potent anticancer activity," on Tuesday, April 20, 2010, from 9:00 am – 12:00 pm EDT in Exhibit Hall A-C, Poster Section 24, during the "Experimental and Molecular Therapeutics" session.

Shares of Rexahn closed the day at $2.59, up 44 cents or 20%. The stock was highlighted today on BioMedReports.

After the bell Thursday:

Boston Scientific Corporation (NYSE:BSX) after the bell today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs), and that it will immediately resume distribution of its COGNIS® CRT-Ds and TELIGEN® ICDs. The Company is positioned to fully meet customer demand for COGNIS and TELIGEN within 24 hours. COGNIS and TELIGEN represent virtually all of the Company's defibrillator implant volume in the United States. Shares moved up more than 6% on the news.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) after the bell Thursday announced results for the first quarter ended March 31, 2010. Cubist’s total net revenues for the first quarter of 2010 increased 19% to $144.1 million from $121.1 million in the first quarter of 2009. This increase was attributable primarily to Cubist’s net sales of CUBICIN® (daptomycin for injection) in the United States, which increased 20% to $135.3 million in the first quarter of 2010 from $112.4 million in the first quarter of 2009.

Hansen Medical, Inc. (NASDAQ:HNSN), after the bell today announced that it intends to offer shares of its common stock in an underwritten public offering. Piper Jaffray & Co. will be the sole underwriter for the offering.

Pharmacyclics, Inc. (Nasdaq:PCYC) today announced multiple presentations covering its Btk and HDAC programs at the American Association for Cancer Research (AACR) 2010 Annual Meeting being held April 17-21 in Washington, DC. "We are continuing our research to expand the clinical indications for the drugs in our pipeline," said Dr. Joseph J. Buggy, Vice President of Research. "For example, while the Btk inhibitor PCI-32765 continues to show promise in clinical trials in patients with B cell lymphomas and leukemias, we are now seeing preclinical evidence that the compound may also be efficacious in mast cell-driven cancers, which include certain pancreatic tumors and melanomas. In addition, our HDAC inhibitor PCI-24781 is now showing synergy with bortezomib in several indications. Based on this discovery, and our previous work, we are planning Phase I/II trials with PCI -24781 in combination with a number of other chemotherapeutics in collaboration with our ex-US global partner, Les Laboratories Servier."

Watson Pharmaceuticals, Inc. (NYSE:WPI), after the bell today announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for metoprolol succinate extended-release tablets USP in the 100 and 200 mg strengths, the generic equivalent to AstraZeneca's Toprol XL® tablets. Watson intends to begin shipping the product next week.

Toprol XL® 100 and 200 mg and its generic equivalents had total U.S. sales of approximately $403 million for the twelve months ending February 2010, according to IMS Health. Metoprolol succinate extended-release is a beta-blocker used to treat angina, heart failure and high blood pressure.

XenoPort, Inc. (Nasdaq:XNPT) after the market closed announced that the European Patent Office (EPO) Opposition Division ruled that the European patent for the composition of matter of XP13512 (European Patent No. 1 404 324) is valid. This favorable decision means that XenoPort retains composition-of-matter protection on multiple forms of XP13512 molecules, and its patent continues to be valid in Austria, Belgium, Switzerland and Liechtenstein, Cyprus, Germany, Denmark, Spain, Finland, France, UK, Greece, Ireland, Italy, Luxembourg, Monaco, The Netherlands, Portugal, Sweden and Turkey until June 2022.

XP13512 is a new chemical entity that is being developed for restless legs syndrome, neuropathic pain and migraine prophylaxis. This investigational compound, also known as Horizant™ (gabapentin enacarbil) in the United States, is not presently marketed anywhere in the world.

In news from earlier in the day:

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board:ACCP.ob), jumped higher after the biopharmaceutical company specializing in products for cancer and supportive care, announced today that it is collaborating with leading expert in oral mucositis, Stephen T. Sonis, DMD, DMSc, Chief of the Division of Oral Medicine at the Dana Farber Cancer Institute and Program Director for Supportive Cancer Care at Clinical Assistance Programs, LLC, to further advance ongoing marketing and reimbursement efforts for MuGard. Together with Dr. Sonis, Access Pharma will develop a program to generate additional clinical data to further support the Company's marketing and reimbursement initiatives surrounding the U.S. commercial launch of its lead product, MuGard - a FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Shares were up 20 cents to $2.75.

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today presented data from the Company's ongoing Phase 1 clinical trial of ACH-1625 to treat hepatitis C (HCV) at the European Association for the Study of the Liver's (EASL) International Liver Congress taking place at the Reed Messe Wien Congress Center in Vienna, Austria from April 14-18, 2010.

Advaxis, Inc., (OTCBB: ADXS), initiated the Company’s first clinical trial site in its randomized, single blind, placebo-controlled, Phase 2 clinical trial of ADXS11-001 for the treatment of cervical intraepithelial neoplasia (CIN). The study is designed to assess the safety and efficacy of ADXS11-001 for the treatment of CIN grade 2/3 commonly known as cervical dysplasia.

Æterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), flew higher as the late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer. Previously, agreement was reached with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the pivotal studies in each of the lead indications, which will be sponsored by Keryx Biopharmaceuticals Inc., (NASDAQ:KERX), Æterna Zentaris's licensee for perifosine in North America. Shares of AEterna moved up 19.5% or 27 cents, closing the day at $1.66.

Anadys Pharmaceuticals, Inc. (Nasdaq:ANDS) moved higher after the company announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care (SOC) achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.

The preliminary analysis of results through eight weeks also showed that ANA598 400 mg bid plus SOC was well tolerated, with an adverse event profile comparable to SOC alone. As seen before at 200 mg bid, no patient experienced viral breakthrough on ANA598.

"The data for ANA598 400 mg bid through eight weeks demonstrates potent antiviral activity and a favorable safety profile, as was seen previously at 200 mg bid," said Steve Worland, Ph.D., President and CEO of Anadys.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) moved higher today after the company announced the appointment of Robert M. Whelan, Jr., a highly regarded financial and business advisor and entrepreneur, to its Board of Directors. Mr. Whelan, 58, has more than thirty-five years of corporate finance and investment banking experience, including leadership positions at Volpe Brown Whelan, Prudential Securities, and Hambrecht & Quist.

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The data were presented in two posters at the American Academy of Neurology (AAN) Annual Meeting in Toronto, Canada. Randall Kaye, MD, AVANIR’s Chief Medical Officer said: "The new lower dose formulations of Zenvia have maintained statistically significant and clinically meaningful efficacy while providing an improved safety and tolerability profile relative to the original higher dose formulation. We plan to file our full response with the FDA within the next few weeks and expect an approval decision on the PBA application before the end of this year."

Biomerica, Inc. (OTC.BB:BMRA) today reported net income before taxes for the quarter ended February 28, 2010 of $133,625 compared to net income before tax benefit of $218,902 for the same period in fiscal 2009. For the nine months ended February 28, 2010 the company reported a net loss of $164,147 compared to a net income of $314,540 during the same period in the previous fiscal year. The net loss for the nine months ended February 29, 2010 was primarily due to non-recurring move expenses associated with the move to a new building.

Cardica, Inc. (Nasdaq:CRDC) soared more than 30% today after the company announced the publication of a study demonstrating that the use of its anastomosis (stapling) devices provides a safe and effective means to connect arterial grafts during beating-heart coronary artery bypass graft (CABG) procedures. The study, which was published in the March/April issue of the official journal of the International Society of Minimally-Invasive Cardiothoracic Surgery, Innovations, evaluated the safety and efficacy of Cardica's C-Port xA® Distal and Flex-A® Anastomosis Systems (C-Port xA and Flex-A) during beating-heart coronary artery bypass graft (CABG) procedures. Results showed that Cardica's anastomosis systems connected arterial grafts consistently and effectively during bypass procedures performed on a beating heart without the use of a heart-lung machine, and that these grafts remained open in short and mid-term follow-up. According to the study, the C-Port xA and Flex-A stapling devices consistently and reproducibly connected an arterial graft with the push of a button in approximately two minutes. Shares closed at $2.50, moving 60 cents, up 31.58%.

Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) today announced it has conducted an immediate reduction in force of 36 employees. The Company expects the reduction in force and elimination of previously planned increase in commercial personnel along with a reduction in planned operating expenses to result in savings of approximately $16 million in 2010. The Company's total projected operating expenses, excluding equity based compensation, are expected to be approximately $60 million in 2010, which is a 21% reduction from its previously projected estimates. As a result of reducing these expenses, the Company is targeting an average net operating burn rate of approximately $4.4 million per month starting in the second quarter of 2010.

Celsion Corporation (Nasdaq:CLSN) traded higher today after the company reported that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006. "The fact that some of these patients were refractory and had prior treatment makes these results even more impressive," remarked Michael H. Tardugno, President & Chief Executive Officer of Celsion Corporation. "The addressable population could be even larger than we imagined before, considering the patient in remission had earlier treatments that were unsuccessful. Additionally, Professor Poon's report that of the 28 treated tumors, 87.5% demonstrated a complete ablation rate at 28 days, suggests improvement in RFA's efficacy to successfully treat local lesions."

Charles River Laboratories, Inc. (NYSE: CRL), today announced the Company’s Shanghai facility became the first preclinical laboratory in China to receive a Certificate of Good Laboratory Practice (GLP) compliance from an Organization for Economic Cooperation and Development (OECD) member country. The certificate acknowledges the site is operating in compliance with OECD Principles of GLP for both toxicology and laboratory services.

CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that preclinical data on its discovery of novel synergistic drug combinations for the treatment of cancer will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC. These preclinical studies reinforce the rationale for investigation of A2A and ?2AR agonists in the treatment of multiple myeloma and other B-cell malignancies and highlight the power of the CombinatoRx combination high throughput screening (cHTS™) technology to interrogate combination activity across large panels of cancer cells to identify novel mechanisms for therapeutic application.

Cynosure, Inc. (Nasdaq:CYNO) today announced the presentation of a new study that demonstrates the clinical benefits of using a 1440 nm wavelength in laser-assisted lipolysis to disrupt fat tissue and tighten skin through tissue coagulation. The study, led by Barry DiBernardo, M.D., Medical Director of New Jersey Plastic Surgery, is one of six Cynosure-related abstracts being presented this week at the 2010 American Society for Laser Medicine and Surgery (ASLMS) Annual Conference in Arizona.

Emisphere Technologies, Inc. (OTCBB:EMIS) tracked higher today after the company announced that Novartis Pharma AG has initiated a second Phase I trial for an oral PTH1-34 which uses Emisphere's Eligen(R) Technology, and is in development for the treatment of postmenopausal osteoporosis. Emisphere Technologies is a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen(R) Technology. Shares were up more than 7% on the news.

Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the company has been granted approval to market its Novation® primary hip replacement system in Japan, a robust orthopaedics market where hip replacement surgeries outnumber knee replacement procedures. "Expanding our hip implant sales in Japan is a significant opportunity and one for which we are well positioned," said Exactech President David Petty.

Genzyme Corp. (NASDAQ: GENZ) today announced that the results from its Late-Onset Treatment Study (LOTS) have been published in today’s New England Journal of Medicine. The study was undertaken to evaluate the safety and efficacy of Myozyme (alglucosidase alfa) in older children and adults with Pompe disease.

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced today that positive interim data from a Phase 1 clinical trial of IMO-2125, a Toll-like Receptor 9 (TLR9) agonist, in null responder patients with chronic hepatitis C virus (HCV) infection were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL). "Results from this first-in-man trial confirm the intended mechanism of action of IMO-2125. Based on these data, we have extended the trial to a fifth dose level and are evaluating dosage and treatment schedules in preparation for a planned Phase 2 trial in combination with ribavirin in the null responder HCV patient population," said Robert Arbeit, M.D., Vice President of Clinical Development at Idera. "In parallel we are conducting a Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve HCV patients."

INVO Bioscience, Inc. (OTC.BB:IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced today that the product registrations required for sale have been completed for Bulgaria in Europe and Venezuela, South America.

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson’s disease (PD). IPX066 is an investigational extended release carbidopa-levodopa product intended to rapidly achieve and sustain effective blood concentrations of levodopa, potentially improving PD clinical symptom management. This is the first of two Phase III studies designed to support marketing approval of IPX066 in Parkinson’s disease.

In a separate announcement Thusday, Impax announced that it has amended its 2008 co-promotion agreement with Wyeth, now a wholly owned subsidiary of Pfizer. Impax will now detail Lyrica® (pregabalin) CV for use as adjunctive therapy for adult patients with partial onset seizures to neurologists effective April 1st. Impax will discontinue detailing Pristiq® (desvenlafaxine extended-release tablets).

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that Roche has provided a favorable update related to its plans to apply for marketing approval of trastuzumab-DM1 (T-DM1) in the US.

T-DM1 comprises ImmunoGen’s DM1 cancer-cell killing agent linked to the HER2-targeting antibody, trastuzumab, developed by Genentech, a wholly owned member of the Roche Group. T-DM1 is in global development by the Roche Group under a collaboration agreement between Genentech and ImmunoGen.

InterMune, Inc. (Nasdaq:ITMN) today announced results of all three cohorts from a 15-day Phase 1b multiple-ascending-dose (MAD) study of low doses of danoprevir (also known as RG7227 and ITMN-191) boosted by low-dose ritonavir (RTV) in patients chronically infected with hepatitis C virus (HCV) genotype-1. The ritonavir-boosted combination showed a favorable safety and tolerability profile. The most commonly reported adverse events were headache, nausea and diarrhea and these had a similar incidence to previously reported studies of danoprevir in combination with standard of care. Dan Welch, Chairman and CEO of InterMune commented, "Importantly, 18 of 25 patients (72%) treated with ritonavir-boosted danoprevir had HCV RNA levels below the limit of detection after only 15 days in this study. These results are at least as strong as those of the 14-day observation period of the 12 week Phase 2b study using un-boosted, high doses of danoprevir with exposure substantially higher than ritonavir-boosted doses. The potential impact of lower systemic exposure on the long-term safety profile of danoprevir will be further evaluated in future studies. The collective results to date appear to confirm that our objective with ritonavir-boosting is realistic."

Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today reported updated long-term efficacy and safety data on Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of hyperphosphatemia (elevated phosphate levels) from an open-label extension study in patients with end-stage renal disease (ESRD) who are on dialysis. The Company's Phase 3 clinical program of Zerenex as a treatment for hyperphosphatemia in patients with end-stage renal disease who are on dialysis is pending commencement under a Special Protocol Assessment (SPA) agreement with the FDA. Ron Bentsur, CEO of Keryx Biopharmaceuticals, commented, "This long-term data provides further evidence of the potential utility of Zerenex as an effective phosphate binder. Also of importance, is Zerenex's potential ability, as an iron-based phosphate binder, to lower the need for IV-iron and/or EPO in this patient population, which could be another advantage, compared to the currently marketed phosphate binders. We intend to monitor for this potential benefit in our upcoming Phase 3 program."

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) shot up today in relation to a positive article here on BioMedReports. The stock moved up 12% or 18 cents, closing the session at $1.65.

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that preclinical data for its novel drug candidate, M402, will be presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR). The meeting will be held April 17-21, 2010 in Washington, DC.

Mylan Inc. (Nasdaq:MYL) today announced that in accordance with its 2.139 million preferred stock issuance, the company has declared its quarterly dividend of $16.25 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share) payable on May 17, 2010, to holders of preferred stock of record as of May 1, 2010.

NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.

Par Pharmaceutical Companies, Inc. (NYSE:PRX) today announced that the U.S. District Court for the District of Delaware has ruled in favor of Par in its challenge of the University of Missouri's patents relating to omeprazole/sodium bicarbonate capsules (20 mg/1.1 g and 40 mg/1.1 g) and powders for oral suspension (20 mg/1.68 g and 40 mg/1.68 g), which are listed in the Orange Book for Santarus's Zegerid® product. Par earlier announced that it had filed an ANDA seeking marketing approval for generic omeprazole/sodium bicarbonate capsules and powders for oral suspension, and that it was the first-filed ANDA with respect to the Zegerid product.

Par currently has tentative approval on both strengths of the Zegerid capsule product. Par intends to review its options with respect to its omeprazole/sodium bicarbonate ANDA.

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has been named as an authorized generic partner by Ferndale Laboratories and has launched an authorized generic of Analpram HC® Cream. Perrigo will also have the opportunity in the future to launch other Ferndale products as the authorized generic distributor.

Analpram HC® Cream is a topical anesthetic and corticosteroid combination and is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and had sales of approximately $24 million for the 12 months period prior to generic market formation of last year, as measured by Wolters Kluwer Health.

Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, will showcase their Attrius™ PET system at MedAxiom’s Spring Conference in Washington D.C., April 16th-18th. MedAxiom is the largest service provider, information resource and networking organization exclusively for cardiology practices, representing over 5400 physicians and 300 Cardiology practices across the United States.

Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that it believes that it has regained compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.

Senetek PLC (OTC Bulletin Board:SNKTY.ob), a life sciences company engaged in the development of technologies that target the science of healthy aging, announced results for the fourth quarter and year ended December 31, 2009. Mr. Ryan, Senetek's new Chairman and Chief Executive Officer, stated, "I am optimistic about the new direction in which we will be taking Senetek. We are continuing to search for and evaluate new business opportunities for the Company. Additionally we are making solid strides at optimizing the value of our existing life segments and expect to be updating the investment community on these developments as progress is made."

Stemgent, Inc. and Pfizer Inc. (NYSE: PFE) today announced a collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community through Stemgent. Stemgent provides research tools and services to institutions, companies and universities in advancing in vitro and in vivo non-human stem cell research.

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from several studies demonstrating that laquinimod, a novel, investigational once-daily oral immunomodulator for relapsing remitting multiple sclerosis (RRMS) may have neuroprotective properties in addition to its anti-inflammatory effects. These studies were presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN).

New data from studies in RRMS patients demonstrate that treatment with laquinimod results in a significant increase in brain derived neurotrophic factor, a key protein responsible for the maintenance of mature neurons.

ULURU Inc. (NYSE Amex: ULU) announced today that the company will present clinical evidence at the 2010 joint annual meeting of the Symposium on Advanced Wound Care and the Wound Healing Society (SAWC/WHS) in Orlando, Florida, April 17-20. SAWC/WHS is the premier wound care educational program within this clinical field and is the largest annual gathering of wound care clinicians in the United States.

XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced it has received a $1 million milestone payment from Takeda Pharmaceutical Company Limited (TSE4502:Takeda) for achieving a pre-established preclinical milestone under the companies' 2006 collaboration agreement, which also calls for additional future milestone payments and royalties on product sales. In the collaboration, XOMA is using its extensive collection of antibody discovery, development and optimization technologies to discover therapeutic antibodies against multiple targets selected by Takeda.

Also Thursday:

Baxter International Inc. (NYSE:BAX) announced today that Ludwig Hantson, Ph.D. has been appointed corporate vice president and president, International.

C. R. Bard, Inc. (NYSE: BCR) today announced that it will host a conference call on Thursday, April 22, 2010 at 5:00 PM EDT, to discuss the company’s first quarter 2010 operating results and to provide financial guidance for the second quarter of 2010.

Genzyme Corp. (NASDAQ: GENZ) and Relational Investors LLC announced today that they have amended their mutual cooperation agreement and that Ralph Whitworth, principal and co-founder of Relational, has been elected to Genzyme’s board of directors, effective immediately.

Health Grades, Inc. (Nasdaq: HGRD) today announced plans to release first quarter results for the period ended March 31, 2010 before the market opens on Wednesday, April 21, 2010.

Exelixis, Inc. (NASDAQ: EXEL) announced today that George A. Scangos, PhD, the company’s president and chief executive officer, will present at the Deutsche Bank 35th Annual Health Care Conference at 9:20 a.m. EDT / 6:20 a.m. PDT on Wednesday, May 5, 2010 in Boston. Mr. Scangos will discuss the company’s corporate strategy, development pipeline, financial results and financial outlook.

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today announced that it intends to offer, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering.

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its first quarter 2010 financial results on Tuesday, May 4, 2010.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has acquired Proxeon A/S, an innovative supplier of products for proteomics analysis headquartered in Odense, Denmark.

Walgreens (NYSE: WAG) (NASDAQ: WAG) has received recognition as "Private-Sector Employer of the Year" by CAREERS & the disABLED magazine for its commitment to recruiting, hiring and promoting people with disabilities.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter